View Item 

Show simple item record

On best practices: The Institute of Medicine scheme for developing, validating, and demonstrating clinical utility of omics‐based diagnostic and predictive tests
dc.contributor.authorSauer, Saschaen_US
dc.date.accessioned2014-01-08T20:35:09Z
dc.date.available2015-02-03T16:14:40Zen_US
dc.date.issued2013-12en_US
dc.identifier.citationSauer, Sascha (2013). "On best practices: The Institute of Medicine scheme for developing, validating, and demonstrating clinical utility of omics‐based diagnostic and predictive tests." PROTEOMICS – Clinical Applications 7(11-12): 748-755.en_US
dc.identifier.issn1862-8346en_US
dc.identifier.issn1862-8354en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/102242
dc.publisherNational Academies Pressen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherTestsen_US
dc.subject.otherDiagnosticsen_US
dc.subject.otherInstitute of Medicineen_US
dc.subject.otherOmicsen_US
dc.titleOn best practices: The Institute of Medicine scheme for developing, validating, and demonstrating clinical utility of omics‐based diagnostic and predictive testsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/102242/1/prca1506.pdf
dc.identifier.doi10.1002/prca.201300041en_US
dc.identifier.sourcePROTEOMICS – Clinical Applicationsen_US
dc.identifier.citedreferenceFarrah, T., Deutsch, E. W., Kreisberg, R., Sun, Z. et al., PASSEL: the PeptideAtlas SRMexperiment library. Proteomics 2012, 12, 1170 – 1175.en_US
dc.identifier.citedreferenceSimon, R. M., Paik, S., Hayes, D. F., Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 2009, 101, 1446 – 1452.en_US
dc.identifier.citedreferencePotti, A., Dressman, H. K., Bild, A., Riedel, R. F. et al., Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 2006, 12, 1294 – 1300.en_US
dc.identifier.citedreferenceBaggerly, K. A., Coombs, K. R., Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high‐throughput biology. Ann. Appl. Stat. 2009, 3, 1309 – 1334.en_US
dc.identifier.citedreferenceZhang, Z., Chan, D. W., The road from discovery to clinical diagnostics: lessons learned from the first FDA‐cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 2995 – 2999.en_US
dc.identifier.citedreferenceUS Food and Drug Adminstration, FDA clears a test for ovarian cancer. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm182057.htm. Retrieved May 5, 2011. Accessed August 23, 2013.en_US
dc.identifier.citedreferenceZhang, Z., Bast, R. C., Jr., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882 – 5890.en_US
dc.identifier.citedreferenceFung, E. T., A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem. 2010, 56, 327 – 329.en_US
dc.identifier.citedreferenceAgency for Healthcare Research and Quality (AHRQ), Genomics test for ovarian cancer detection and management. AHRQ, Rockville, MD 2006.en_US
dc.identifier.citedreferenceZhang, Z., Chan, D. W., Cancer proteomics: in pursuit of “true” biomarker discovery. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 2283 – 2286.en_US
dc.identifier.citedreferenceCommittee on Assessing Integrity in Research Environments, Integrity in scientific research: creating an environment that promotes responsible conduct. National Academies Press, Washington, DC 2002.en_US
dc.identifier.citedreferenceNational Research Council, International regulatory harmonization amid globalization of drug development: workshop summary. National Academies Press, Washington, DC 2013.en_US
dc.identifier.citedreferenceHood, L., Systems biology and p4 medicine: past, present, and future. Rambam Maimonides Med. J. 2013, 4, e0012.en_US
dc.identifier.citedreferenceRoychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J. et al., Personalized oncology through integrative high‐throughput sequencing: a pilot study. Sci. Transl. Med. 2011, 3, 111ra121.en_US
dc.identifier.citedreferenceRoychowdhury, S., Chinnaiyan, A. M., Advancing precision medicine for prostate cancer through genomics. J. Clin. Oncol. 2013, 31, 1866 – 1873.en_US
dc.identifier.citedreferenceHayes, D. F., Allen, J., Compton, C., Gustavsen, G. et al., Breaking a vicious cycle. Sci. Transl. Med. 2013, 5, 196cm196.en_US
dc.identifier.citedreferenceNational Research Council, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy Of Disease, National Academies Press, Washington, DC 2011.en_US
dc.identifier.citedreferenceOmenn, G. S., in: Ginsgburg, G. S., Willard, H. F. (Eds.), Genomic and Personalized Medicine, Elsevier, New York 2012, pp. 50 – 59.en_US
dc.identifier.citedreferenceMicheel, C. C., Nass, S. J., Omenn, G. S. (Eds.), Evolution of Translational Omics: Lessons Learned and the Path Forward, National Academies Press, Washington, DC 2012.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
prca1506.pdf
Size:
498.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.